Literature DB >> 30651204

Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review.

Katharina Beck1, Christina Andreou2, Erich Studerus2, Ulrike Heitz1, Sarah Ittig2, Letizia Leanza1, Anita Riecher-Rössler3.   

Abstract

BACKGROUND: Research on patients at clinical high risk (CHR) for psychosis has so far mainly focused on those with transition to frank psychosis (CHR-T patients). However, the majority of CHR patients do not transition (CHR-NT patients) and relatively little information is available on their clinical and functional outcome.
METHODS: We conducted a systematic review on clinical and functional long-term outcome of CHR-NT patients. Studies were included if they had an average follow-up period of at least 24 months and reported on long-term outcome of CHR-NT patients in one or more of the following domains: (non-)remission from CHR, prevalence of clinical symptoms and/or clinical diagnoses (axis I and II), and psychosocial functioning.
RESULTS: Ten publications from seven different single or multicenter studies with average follow-up durations of 2-7.5 years could be included. At the last follow-up assessment 28-71% of CHR-NT patients were not remitted from their CHR and 22-82% still had at least one clinical diagnosis. Approximately half of CHR-NT patients presented with poor psychosocial outcome at 2-year and 6-year follow-up.
CONCLUSIONS: The results suggest that, in the long-term, the majority of CHR-NT patients are not in full clinical remission and seem to suffer from one or more clinical disorders and psychosocial impairments. Since relatively few studies could be identified, further research is required to better understand the trajectories and clinical needs of CHR-NT patients.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Non-converters; Non-psychotic disorders; Prodromal; Psychosocial; Remission

Year:  2019        PMID: 30651204     DOI: 10.1016/j.schres.2018.12.047

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

Review 1.  Potential Roles of Redox Dysregulation in the Development of Schizophrenia.

Authors:  Diana O Perkins; Clark D Jeffries; Kim Q Do
Journal:  Biol Psychiatry       Date:  2020-04-02       Impact factor: 13.382

2.  Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.

Authors:  JunJie Wang; TianHong Zhang; LiHua Xu; YanYan Wei; XiaoChen Tang; YeGang Hu; HuiRu Cui; YingYing Tang; ChunBo Li; Zheng Ling; JiJun Wang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-09-18       Impact factor: 5.270

3.  Pluripotential Risk and Clinical Staging: Theoretical Considerations and Preliminary Data From a Transdiagnostic Risk Identification Approach.

Authors:  Jessica A Hartmann; Patrick D McGorry; Louise Destree; G Paul Amminger; Andrew M Chanen; Christopher G Davey; Rachid Ghieh; Andrea Polari; Aswin Ratheesh; Hok Pan Yuen; Barnaby Nelson
Journal:  Front Psychiatry       Date:  2021-01-08       Impact factor: 4.157

4.  Clinical high-risk criteria of psychosis in 8-17-year-old community subjects and inpatients not suspected of developing psychosis.

Authors:  Frauke Schultze-Lutter; Petra Walger; Maurizia Franscini; Nina Traber-Walker; Naweed Osman; Helene Walger; Benno G Schimmelmann; Rahel Flückiger; Chantal Michel
Journal:  World J Psychiatry       Date:  2022-03-19

Review 5.  Neuroimaging Markers of Resiliency in Youth at Clinical High Risk for Psychosis: A Qualitative Review.

Authors:  Teresa Vargas; Katherine S F Damme; Arielle Ered; Riley Capizzi; Isabelle Frosch; Lauren M Ellman; Vijay A Mittal
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-06-10

Review 6.  Advances in clinical staging, early intervention, and the prevention of psychosis.

Authors:  Tina Gupta; Vijay A Mittal
Journal:  F1000Res       Date:  2019-11-29

Review 7.  Structural and functional imaging markers for susceptibility to psychosis.

Authors:  Christina Andreou; Stefan Borgwardt
Journal:  Mol Psychiatry       Date:  2020-02-17       Impact factor: 15.992

8.  Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months.

Authors:  C Wenneberg; B Y Glenthøj; L B Glenthøj; B Fagerlund; K Krakauer; T D Kristensen; C Hjorthøj; R A E Edden; B V Broberg; K B Bojesen; E Rostrup; M Nordentoft
Journal:  Eur Psychiatry       Date:  2020-08-07       Impact factor: 5.361

9.  Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis.

Authors:  Gonzalo Salazar de Pablo; Livia Soardo; Anna Cabras; Joana Pereira; Simi Kaur; Filippo Besana; Vincenzo Arienti; Francesco Coronelli; Jae Il Shin; Marco Solmi; Natalia Petros; Andre F Carvalho; Philip McGuire; Paolo Fusar-Poli
Journal:  Epidemiol Psychiatr Sci       Date:  2022-01-19       Impact factor: 6.892

10.  Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis.

Authors:  Gonzalo Salazar de Pablo; Filippo Besana; Vincenzo Arienti; Ana Catalan; Julio Vaquerizo-Serrano; Anna Cabras; Joana Pereira; Livia Soardo; Francesco Coronelli; Simi Kaur; Josette da Silva; Dominic Oliver; Natalia Petros; Carmen Moreno; Ana Gonzalez-Pinto; Covadonga M Díaz-Caneja; Jae Il Shin; Pierluigi Politi; Marco Solmi; Renato Borgatti; Martina Maria Mensi; Celso Arango; Christoph U Correll; Philip McGuire; Paolo Fusar-Poli
Journal:  EClinicalMedicine       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.